SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Speech Bubble Puzzle and Discussion
Patents
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that convert intravenous drugs into injectable versions.
March 5, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Creative collage picture human hands hold scissors banknote cash cut money inflation crisis funds salary devaluation drawing background.
GLP-1
Novo Launches DTC Program for Wegovy, Cutting Price to $499 a Month
Novo Nordisk’s NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less than half of its list price.
March 5, 2025
 · 
2 min read
 · 
Annalee Armstrong
Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.
Mergers & acquisitions
Jazz Expands Cancer Expertise With $935M Chimerix Buy
At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 K27M-mutated diffuse glioma.
March 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Sign outside BioNTech's building in Germany
Vaccines
FDA Pauses Study of BioNTech’s Malaria Shot as Problems for Vaccine Space Mount
The vaccine space has been battered by strong headwinds in recent weeks, including high-level disruptions to FDA and CDC advisory committee meetings.
March 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative photo poster trend art collage image of hands hold poster chart development statistics success growth economy progress.
Rare diseases
Priority Review Vouchers: By the Numbers
A BioSpace analysis of all 80 priority review vouchers that have been handed out across the three FDA programs that offer them found that 2024 was the busiest year yet. Companies have disclosed spending $513 million on vouchers that were earned in 2024 so far.
March 5, 2025
 · 
1 min read
 · 
Annalee Armstrong
Illustration of two hands, one thumbs up and one thumbs down
Mergers & acquisitions
Acelyrin Rejects Concentra’s Buyout Offer in Favor of Alumis Merger
Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.
March 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Man hand with magnifying glass. Yellow ray coming from loupe. Conducting check, information search and analysis concept. Spy, accountant, auditor job in abstract style. High quality photo
Regulatory
Novo, Sanofi Hit With Anti-Competitive Probe in South Africa: Bloomberg
The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to lower drug prices.
March 5, 2025
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
 · 
1 min read
 · 
Lori Ellis
Podcasts
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie and Eli Lilly strike mid-sized deals in obesity and molecular glues, priority review vouchers set to take a hit and immuno-oncology matures.
March 5, 2025
 · 
1 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS